Abstract: The present invention relates to a novel human Ependymin protein which is a member of the ependymin family. In particular, isolated nucleic acid molecules are provided encoding the human Ependymin protein. Ependymin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Ependymin activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders.
Abstract: A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.
Type:
Grant
Filed:
February 29, 2000
Date of Patent:
December 9, 2003
Assignee:
Harbor-UCLA Research and Education Institute
Inventors:
Frans J. Walther, Alan J. Waring, Larry M. Gordon, Joseph A. Zasadzinski
Abstract: The present invention relates to novel human proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells and recombinant methods for producing the proteins of the invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
Type:
Grant
Filed:
January 21, 1998
Date of Patent:
November 25, 2003
Assignees:
Human Genome Sciences, Inc., Auckland Uniservices, Limited
Inventors:
Jian Ni, Craig A. Rosen, Reiner Gentz, Jeffrey Y. Su, Geoffrey W. Krissansen, Ping Feng
Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.
Type:
Grant
Filed:
July 14, 2000
Date of Patent:
October 14, 2003
Assignee:
Boston Heart Foundation, Inc.
Inventors:
Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
Abstract: The present invention relates to proteins derived from the coffee bean and DNAs encoding and regulating the expression of at least one of these proteins.
Abstract: A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding a glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt and prefers an octahedral coordination geometry, and/or (c) a plasma component. In this process, the occupancy of an N-linked glycosylation site occupied only in a fraction of a glycoprotein is enhanced. Such culturing is preferably carried out at a temperature of between about 30° C. and 35° C. and/or in the presence of up to about 2 mM of a butyrate salt and/or in the presence of a cell-cycle inhibitor.
Type:
Grant
Filed:
November 27, 2000
Date of Patent:
August 26, 2003
Assignee:
Genentech, Inc.
Inventors:
Dana C. Andersen, Tiffany M. Bridges, Martin Gawlitzek, Cynthia A. Hoy
Abstract: A regulator protein of a two-component signal transduction system in plants and a nucleic acid coding therefor are disclosed. The present invention provided an isolated protein having the amino acid sequence shown in SEQ ID NO:1 in the Sequence Listing or an amino acid sequence having a homology of not less than 30% to the amino acid sequence shown in SEQ ID NO:1, which functions as a regulator protein in a plant, and a nucleic acid coding therefor.
Abstract: A rigidly spaced, cyclodextrin dimers having a preselected breaking point within the spacer sequence so as to controllably release the active pharmaceutically active substance only after it reaches the desired treatment site is described. These preselected breaking points are stable in blood but are cleavable within cells. In preferred embodiments, the cyclodextrin-pharmaceutically active substance complex is targeted to specific sites via incorporation of specific antibodies for the targeted sites, typically by complexing a biotin-avidin system to specific antibodies which thereby targets the complex to a specific site. Once at the site as the complex is taken up into the cell the preselected break point is cleaved and the encapsulated pharmaceutically active substance becomes available for action within the targeted cell.
Abstract: Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.
Type:
Grant
Filed:
May 25, 2000
Date of Patent:
July 29, 2003
Assignee:
Xoma Corporation
Inventors:
Arnold Horwitz, Stephen F. Carroll, David Burke
Abstract: A universal folding method that has been demonstrated to be effective in refolding a variety of very different proteins expressed in bacteria as inclusion bodies has been developed. Representative proteins that can be dissolved and refolded in biologically active form, with the native structure, are shown in Table I. The method has two key steps to unfold and then refold the proteins expressed in the inclusion bodies. The first step is to raise the pH of the protein solution in the presence of denaturing agents to pH greater than 9, preferably 10. The protein solution may be maintained at the elevated pH for a period of up to about 24 hours, or the pH immediately decreased slowly, in increments of about 0.2 pH units/24 hours, until the solution reaches a pH of about 8.0, or both steps used. In the preferred embodiment, purified inclusion bodies are dissolved in 8 M urea, 0.1 M Tris, 1 mM glycine, 1 mM EDTA, 10 mM beta-mercaptoethanol, 10 mM dithiothreitol (DTT), 1 mM redued glutathion (GSH), 0.
Abstract: Disclosed herein is an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1. The isolated polypeptide binds to the DNA binding domain located from −550 to −487 in the promoter of the human TNF-&agr; gene. Additionally, the level of the mRNA transcript encoding the isolated polypeptide is substantially increased in response to LPS stimulation in cultured THP-1 cells.
Abstract: A method for purifying human or other alpha-l proteinase inhibitor (&agr;1-PI) from a solution (which may be derived from the milk of a transgenic animal expressing the &agr;1-PI) which comprises contacting the solution with a cation exchange substrate under conditions sufficient to bind non-tg-&agr;1-PI contaminants to the substrate while not substantially binding tg &agr;1-PI to the substrate. Using the preferred embodiment, the purified tg &agr;1-PI contains as little as 40 pg non-&agr;1-PI-whey protein per mg total protein.
Abstract: The invention provides genes encoding resistance to DNA bioreductive alkylating or cleaving agents and methods of identifying and using those genes.
Type:
Grant
Filed:
August 19, 1996
Date of Patent:
February 25, 2003
Assignee:
Regents of the University of Minnesota
Inventors:
David H. Sherman, Paul R. August, Michael C. Flickinger
Abstract: A DNA molecule coding for a food protein, such as ovalbumin or casein, modified so that the codons for phenylalanine have been omitted or replaced by codons for one or more other metabolisable amino acids. Also a modified edible protein coded for by such a DNA molecule. Such modified proteins are useful in the nutrition of patients suffering from phenylketonuria.
Abstract: This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof.
Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Canf I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
Type:
Grant
Filed:
August 16, 1999
Date of Patent:
December 3, 2002
Assignee:
ImmuLogic Pharmaceutical Corporation
Inventors:
Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
Abstract: The invention provides isolated Hm2 nucleic acids, and their encoded proteins. The present invention provides methods and compositions relating to altering Hm2 concentration and/or composition of plants. The invention further provides expression cassettes, host cells, transgenic plants, and antibody compositions. Also, the invention provides methods of identifying plant transformation by survival of transformed plant cells or tissues on a cyclic tetrapeptide toxin. The invention further provides methods of imparting disease resistance to plants susceptible to fungal pathogens, which utilize cyclic tetrapeptide toxins.
Type:
Grant
Filed:
January 24, 2001
Date of Patent:
November 26, 2002
Assignee:
Pioneer Hi-Bred International, Inc.
Inventors:
Steven P. Briggs, Gurmukh Johal, Dilbag Singh Multani
Abstract: The invention provides a human transducin beta-1 subunit (TBS) and polynucleotides which identify and encode TBS. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating or preventing diseases associated with expression of TBS.
Type:
Grant
Filed:
January 21, 2000
Date of Patent:
October 15, 2002
Assignee:
Incyte Genomics, Inc.
Inventors:
Olga Bandman, Preeti Lal, Neil C. Corley, Purvi Shah
Abstract: A novel microbial protein is described which appears to have significant homology to plant expansin proteins and has the ability to weaken filter paper and swell cellulose. A DNA is described which encodes the novel protein.
Type:
Grant
Filed:
July 9, 1998
Date of Patent:
October 1, 2002
Assignee:
Genecor International, Inc.
Inventors:
Barbara A. Swanson, Michael Ward, Merja Penttilä, Jaakko Pere, Markku Saloheimo